The Full Wiki

More info on Capecitabine

Capecitabine: Quiz


Question 1: May inhibit cytochrome CYP2C9 enzyme, and therefore increase levels of substrates such as ________ and other substrates of CYP2C9.

Question 2: May interact with ________ and increase bleeding risk.

Question 3: halogenated/ribonucleotide reductase inhibitors (________, Clofarabine, Fludarabine)

Question 4: Capecitabine (INN) (pronounced /keɪpˈsaɪtəbiːn/) (Xeloda, Roche) is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and ________.
Hepatocellular carcinomaColorectal cancerCrohn's diseaseStomach cancer

Question 5: Capecitabine is a prodrug, that is enzymatically converted to ________ in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Question 6: For mild renal dysfunction (________ 30-50 mL/min), it is recommended to reduce dose by 25%.
Renal physiologyNephronRenal functionAnion gap

Question 7: In the UK, capecitabine is approved by the ________ (NICE) for colon and colorectal cancer, and locally advanced or metastatic breast cancer.
EnglandCity University LondonWalesNational Institute for Health and Clinical Excellence

Question 8: Gastrointestinal: ________ (sometimes severe), nausea, stomatitis
Traveler's diarrheaGastroenteritisVomitingDiarrhea

Question 9: Metastatic ________ - used in combination with docetaxel, after failure of anthracycline-based treatment.
Breast cancer classificationLung cancerBreast cancerMammary ductal carcinoma

Question 10: Also as monotherapy, if the patient has failed ________-based treatment, and if anthracycline-based treatment has either failed or cannot be continued for other reasons (i.e., the patient has already received the maximum lifetime dose of an anthracycline).

Got something to say? Make a comment.
Your name
Your email address